1-10 of 31 results
Item icon
50 mg, 150 mg, and 250 mg NUVIGIL® under license beginning in June 2016, or earlier … NUVIGIL® is an FDA-approved prescription medicine used to improve wakefulness in …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1688889&highlight=View duplicates

Item icon
50 mg, 150 mg, and 250 mg NUVIGIL® under license beginning in June 2016, or earlier … NUVIGIL® is an FDA-approved prescription medicine used to improve wakefulness in …
Size: 10KB

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle_print&id=1688889&highlight=View duplicates

Web Page
continue to focus on our current NUVIGIL® indications and we remain committed to … insomnia. Full prescribing information for NUVIGIL® is available at www.NUVIGIL.com. …
Date: 4/21/2014 Size: 50KB

http://www.tevapharm.com/media/news/pages/2013/1851019.aspx?category=clinical studiesView duplicates

Item icon
TEVA Investor Relations - Teva Reports Third Quarter 2012 Results … Notice of Special Meeting of Shareholders 2014 – Proxy Statement … The National Network of Excellence in Neuroscience (NNE) …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1752738View duplicates

Item icon
TEVA Investor Relations - Teva Reports Second Quarter 2012 Results … Notice of Special Meeting of Shareholders 2014 – Proxy Statement … The National Network of Excellence in Neuroscience …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1721484View duplicates

Item icon
The Official TEVA News Releases - Investor Relations web site. Teva is the global leader in generic pharmaceuticals and has one of the broadest product portfolios in the industry …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-news&nyo=1View duplicates

Item icon
Notice of Special Meeting of Shareholders 2014 – Proxy Statement … The National Network of Excellence in Neuroscience (NNE) … Fourth Quarter 2013 Net Revenues of $5.4 Billion and Full Year …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1897548&highlight=View duplicates

Item icon
TEVA Investor Relations - Teva Provides 2014 Financial Outlook … Notice of Special Meeting of Shareholders 2014 – Proxy Statement … The National Network of Excellence in Neuroscience (NNE) …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1883417&highlight=View duplicates

Item icon
The Official TEVA News Releases - Investor Relations web site. Teva is the global leader in generic pharmaceuticals and has one of the broadest product portfolios in the industry …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-news&nyo=2View duplicates

Item icon
Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated with … is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved for use in …

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&id=1777093&highlight=View duplicates